Uncategorized-EN
Improving Communication between Patients and Oncologists, Part 1: Rethinking Our Roles
If you are a sarcoma patient, a physician, or a patient advocate, you know that medical encounters are sometimes frustrating and dissatisfying for those involved.
Communication can go wrong in many ways, both big and small.
This is particularly unfortunate when it happens in encounters between patients and oncologists, as there is so much at stake.
Read MoreTNG908 in MTAP-deleted solid tumors including soft tissue and bone sarcomas
Safety and tolerability of TNG908 in MTAP-deleted solid tumors including sarcomas Agents: TNG908 Phase I/II Status Closed for recruitment Sponsor Tango Therapeutics Further information on Clinicaltrials.gov. Phase I/II study in solid tumor patients with a specific genetic mutation, a MTAP deletion, including sarcomas (soft tissue and bone sarcomas) WHO is the trial for?…
Read MoreThe Value of Patient Involvement in Research
We hear a lot about patient involvement in research these days. It’s a hot topic. But what does it actually mean?
And more importantly, what benefits does it bring?
Read MoreLooking back on 2022 and ahead to 2023
How was 2022 for your organization? What accomplishments are you proud of?
We at SPAGN are looking back at what we have done in the past year to impact the treatment and survival of sarcoma patients. We also want to look ahead to our plans for the near future.
Read MoreSpain: Sarcoma Patients Spanish Association/Asociación Española de Afectados por Sarcoma (AEAS)
Asociación Española de Afectados por Sarcoma (AEAS) Contact Information Email: secretaria@aeasarcomas.org Phone: 0034681301754 Web: https://www.aeasarcomas.eu/ Contact Persons Presidente: Jose Luis Muñoz Vicepresidente: Dr. Antonio Casado Secretario: Orlando Dámaso Organisation profile AEAS, the Sarcoma Patients Spanish Association, is a non profit organization that advocates on behalf of people affected by sarcoma.…
Read MoreIDRX-42 in metastatic and/or unresectable GIST
Trial name: IDRX in advanced GIST Agents: IDRX-42 Phase I/Ib Status Recruiting Sponsor IDRx Inc. This is a Phase 1/1b open-label study of IDRX-42 in metastatic and/or unresectable GIST. Further information can be found on clinicaltrials.gov. WHO is the trial for? Adult patients with confirmed diagnosis of unresectable or metastatic GIST Patients…
Read MoreSunriseLMS: Unesbulin in Advanced Leiomyosarcoma
Agents: Unesbulin vs. Placebo Phase II/III Status Recruiting Sponsor PTC Therapeutics For further information please also consult ClinicalTrials.gov. This study compares the efficacy and safety of unesbulin plus dacarbazine versus placebo plus dacarbazine in advanced LMS who have received at least 1 prior line of systemic therapy. WHO is the trial for?…
Read MoreBrightline-1: Advanced Dedifferentiated Liposarcoma
Treatment of BI 907828 Versus Doxorubicin in Patient With Advanced Dedifferentiated Liposarcoma (Brightline-1) Agents: BI 907828 vs. Doxorubicin Phase II/III Status Closed for recruitment, trial still ongoing (active) Sponsor Boehringer Ingelheim For further information please also consult ClinicalTrials.gov. This is a Phase II/III registration study evaluating the safety and efficacy of BI 907828…
Read MoreGlobal TGCT consensus paper published
The SPAGN expert-patient global consensus paper on the management of TGCT (Tenosynovial Giant Cell Tumor) has been published in “Cancer Treatment Reviews”. Over 50 experts and patient advocates have worked together over months to formalize guidelines based on the available evidence and experience within the expert community. We are happy and proud to bring…
Read More
SPAGN Annual Conference & New Horizons GIST 2023:
Hand in Hand for the first time
Save the Date! 2023 SPAGN Annual Conference May 11-13, 2023 in Dublin/Ireland NEW HORIZONS GIST May 13-15, 2023 in Dublin/Ireland For the first time ever, the SPAGN Annual Conference and the New Horizons GIST Meeting will be held hand in hand. About the SPAGN Annual Conference: Since 2010, SPAEN/SPAGN has organized annual conferences to…
Read More